Summary We have examined the biological properties of CEA6, a human carcinoembryonic antigen (CEA)-specific single-chain Fv (scFv) isolated by phage display, and five related clones derived by affinity maturation and selected for improved off-rate (Kff). All clones bind strongly and specifically to CEA-positive human tumours by immunocytochemistry and show negligible cross-reactivity with normal colon. Flow cytometry of scFv on human liver cells indicates a shift in fine epitope specificity resulting from mutagenesis. All monomeric scFv have been radioiodinated, retaining effectively full binding activity. A single intravenous injection into nude mice bearing human colon tumour xenografts confirms tumour targeting in all cases. As reported in other studies, the kidney is the main route of elimination of scFv at early time points. Tumour binding of the parental antibody CEA6 consistently gives the highest tumour-blood ratios at 24 h (mean 16:1). Clone T06D11, which has a sevenfold reduced K0ff relative to CEA6, showed no difference in tumour uptake at 24 h but persisted at the tumour site for longer than CEA6. This study demonstrates a possible correlation between binding affinity and tumour residence time when examined in this model. Keywords: human scFv; carcinoembryonic antigen; affinity maturation Advances in recombinant antibody technology have allowed many of the problems encountered in antibody targeting of tumours to be overcome (Huston et al, 1993) . Poor tumour penetrance of whole immunoglobulin has been addressed through the use of smaller fragments derived both enzymatically and by recombinant methods (Yokota et al, 1992; Hu et al, 1996; Rowlinson-Busza et al, 1996) . Further advantages of fragments are their rapid extravasation and pharmacokinetic clearance, which are clearly contributing factors in their improved performance as imaging agents (Colcher et al, 1990; Milenic et al, 1991; Verhaar et al, 1995) . Moreover, the immunogenicity of rodent monoclonal antibodies (mAbs) has been reduced either by humanization strategies or by de novo isolation of antibody fragments from combinatorial libraries of human V genes (reviewed by Johnson and Chiswell, 1993) . Rapid expression in bacteria has greatly assisted the study of improved engineered antibody fragments and has avoided timeconsuming and expensive mammalian cell expression systems.
Advances in recombinant antibody technology have allowed many of the problems encountered in antibody targeting of tumours to be overcome (Huston et al, 1993) . Poor tumour penetrance of whole immunoglobulin has been addressed through the use of smaller fragments derived both enzymatically and by recombinant methods (Yokota et al, 1992; Hu et al, 1996; Rowlinson-Busza et al, 1996) . Further advantages of fragments are their rapid extravasation and pharmacokinetic clearance, which are clearly contributing factors in their improved performance as imaging agents (Colcher et al, 1990; Milenic et al, 1991; Verhaar et al, 1995) . Moreover, the immunogenicity of rodent monoclonal antibodies (mAbs) has been reduced either by humanization strategies or by de novo isolation of antibody fragments from combinatorial libraries of human V genes (reviewed by Johnson and Chiswell, 1993) . Rapid expression in bacteria has greatly assisted the study of improved engineered antibody fragments and has avoided timeconsuming and expensive mammalian cell expression systems.
The isolation and characterization of scFv from large phage display libraries has demonstrated several instances where the dissociation constant of the molecule, and more specifically the off-rate (Kodf), is the main predictive factor in performance in in vitro bioassays (Thompson et al, 1996; Schier et al, 1996; Roberts et al, in preparation) . The relationship between binding kinetics and tumour targeting efficiency is rather more complicated, mainly because so many additional factors (tumour size, antigen density and rate of turnover, epitope, size and charge of antibody, dose, isotope and labelling chemistry used, presence of circulating antigen) are known to influence the uptake of radiolabelled antibody into tumours (reviewed by Goldenberg et al, 1990) . Although it is generally thought that the best cancer therapeutic would have a high affinity for antigen and a slow rate of dissociation from the tumour cell surface, this conclusion has been drawn from studies of rodent-derived antibodies. Whether the same will be true of completely human antibodies awaits the outcome of more extensive in vivo studies.
The best means of exploring the role of affinity for antigen in tumour targeting is a parallel comparison of several structurally related targeting molecules, differing from one another only in their affinity (Langmuir et al, 1992; Schlom et al, 1992) . We have developed such a panel of molecules through the structural diversification of scFv CEA6 (Vaughan et al, 1996) , by CDR3 mutagenesis and chain shuffling . We have used radioiodinated scFv of five mutants and the CEA6 parent in nude mice bearing human colon tumour xenografts, to measure the biodistribution at various times after intravenous administration. We have found that, for scFv antibodies whose pharmacokinetic clearance is relatively rapid, a reduction in K, to within an order of magnitude has a relatively modest effect on the association of antibody with tumour.
In the investigation by flow cytometry of CEA specificity of CEA6 and all five affinity-matured scFv, an immortalized human liver cell line was used as a negative control for CEA expression. We made the unexpected observation that, although none of the affinity-matured clones bound to this cell line, a subpopulation of cells was recognized by CEA6. This difference in fine antigenic specificity was not seen when the scFv were used for immunocytochemical staining of sections of normal human liver. However, the result demonstrates how the structural diversification of antibodies during affinity maturation may have unforeseen effects on fine antigenic specificity.
MATERIALS AND METHODS Affinity matured CEA-specific scFv
The antibodies which are the subject of this study have been described in detail in Osbourn et al (1996) . Briefly, the parental clone, CEA6, and all five mutants derived from it (HBB 11, 181 T06D10, T06D4, TO6D 12 and TO6D11) have a range of dissociation constants (Kd) for CEA when measured by surface plasmon resonance, mainly through differences in Koff, with TO6D 1I having the slowest off-rate relative to CEA6 (Table 1) . All six scFv, as well as the positive control MFE23 and negative controls FITC-E2 and Hb-1 (all described further below), had been subcloned for expression from the gene III-containing phagemid vector pCANTAB6 into a pUC 19-derived plasmid.
Growth, expression and purification of scFv Colonies were inoculated into 50 ml of 2TY broth containing 2% (w/v) glucose and 100 .tg ml-' ampicillin (2YTGA) and incubated overnight at 30°C. The overnight culture was added to 500 ml of 2TYA containing 0.1% (w/v) glucose and grown at 30°C in an orbital shaker to an OD600 of 1.0. IPTG was added to 1 mm final concentration and the cultures induced for 3 h at 30°C. Cells were pelleted at 5000 r.p.m. for 10 min in a precooled rotor (4°C; Sorvall GSA) and periplasmic preparations of scFv were made by resuspending the pellets in 25 ml ice-cold 50 mM Tris-HCl pH 8.0, 20% sucrose, 1 mM EDTA and incubating on ice for 15 min. Insoluble material was removed by centrifugation and magnesium chloride was added to 1 mm final concentration. The scFv supernatant was added to prewashed NTA-agarose (Qiagen) and incubated at 4°C overnight for purification by immobilized metal affinity chromatography (IMAC) via the carboxy-terminal hexahistidine tail. Material bound to NTA-agarose was eluted in phosphate buffer containing 250 mm imidazole. Monomeric scFv was fractionated from the eluate by fast protein-liquid chromatography (FPLC) on a Superdex 75 HRI 0/30 column (Pharmacia) and detected on-line by UV absorbance at 280 nm.
SDS polyacrylamide gel electrophoresis (SDS-PAGE)
Samples of FPLC-purified scFv were analysed on 10-15% gradient gels using the Phast electrophoresis system (Pharmacia). For analysis of the proportion of dimeric scFv, gels were run under non-reducing conditions. After electrophoresis the gels were silver stained according to Pharmacia methods.
Enzyme-linked immunosorbent assay (ELISA)
Flexible 96-well microtitre plates (Falcon) which had been coated overnight at 37°C with 50 ng per well CEA (Genzyme) in distilled water were washed three times in phosphate-buffered saline (PBS) and blocked for 2 h at room temperature (RT) in PBS containing 3% (w/v) skimmed milk powder (3MPBS). Plates were washed three times with PBS, then 50 tl per well purified scFv (preblocked with MPBS) was added for 1 h at RT. Plates were washed three times in PBS containing 0.1% (v/v) Tween 20 (Sigma) (PBST) and three times with PBS. Detection of bound scFv was with 1:200 diluted anti-myc tag antibody, 9E10 (Munro and Pelham, 1986) , for 1 h at RT. After washing, the assay was developed with 1:5000 diluted alkaline phosphatase conjugated goat anti-mouse IgG (Pierce) at RT for I h. Plates were washed, rinsed in 0.9% sodium chloride and the chromagenic substrate pNPP (Sigma) was added. Absorbance was measured at 405 nm.
Dissociation constant measurement Surface plasmon resonance (SPR) for measuring the kinetics of scFv binding to CEA immobilized on a BlAcore sensor chip was carried out for all samples used for in vitro and in vivo binding experiments: the methods used have been described previously . Immunocytochemistry IMAC-purified scFv were used to detect CEA expressed in paraffin-embedded formalin-fixed sections from different tissue sources (BioMedix). Sections were de-waxed in Histoclear then washed twice with 100% ethanol, once with 70% ethanol, rehydrated in distilled water (all 5 min each) and rinsed in PBST. Endogenous alkaline phosphatase activity was then blocked with 20% acetic acid for 15 min, rinsed with PBST, then blocked for 1 h in 1% bovine serum albumin (BSA) in PBS (PBSB). After rinsing, monomeric scFv diluted to 10 ,g ml-' in PBSB were applied and incubated in a humidified atmosphere overnight at 4°C. Slides were rinsed three times with PBST (2 min each), then incubated with 1:100 diluted 9E10 in PBSB for 1 h at RT. After rinsing as before, alkaline phosphatase conjugated goat antimouse IgG (Jackson Laboratories; 1:100 diluted in PBS/10% fetal calf serum) was added and the incubation continued for 1 h. Bound antibody was detected with Fast Red substrate, then the section was counterstained with haematoxylin and mounted.
Flow cytometry HeLa cells (1.0 x 101 cells) which had been stably transfected with human CEA, or Chang human liver cells, were incubated with 5 ,ug purified scFv in 100 gl PBS/0.5% BSA for 1 h at RT. Cells were washed once with 10 ml PBS/0.5% BSA, incubated with 9E10 at 25 gg ml-' in 100 .tl PBS/0.5% BSA for I h, then washed and incubated with a 1:200 dilution of FITC-conjugated anti-mouse IgG (Sigma) in 100 gl PBS/0.5% BSA for 1 h. After the final washing step, cell fluorescence was measured using a Coulter-EPISXL-MCL flow cytometer. Fluorescence was measured using the FLI channel (emission below 550 nm) and plotted on a logarithmic scale against the number of cells.
Radioiodination
Eight FPLC-purified, monomeric scFv were labelled with iodine-125 (1251) for biodistribution studies in tumour-bearing mice (see below). Six CEA-specific scFv (CEA6, HBB 11, T06D10, T06D4, T06D12 and TO6D1 1) were selected to span a range of Koff measurements for CEA, as measured by SPR (Table 1 ; . Control scFv were as follows: a human scFv FITC-E2, specific for the hapten fluorescein (Vaughan et al, 1996) was Table 1 Affinity-matured scFv derivatives of CEA6 scFv Origin included as a negative control, while a murine CEA-specific scFv, MFE23, kindly provided by Dr K Chester, Royal Free Hospital, London, UK, was used as a positive control. MFE23 has previously been shown to localize to CEA-expressing tumours in mice and to metastatic liver deposits of colorectal tumours in humans (Chester et al, 1994; Verhaar et al, 1995; Begent et al, 1996) . lodination was carried out using a modification of the lodoGen method (Pimm and Gribben, 1993) . Monomeric scFv were exposed to Na'251 (ICN) in 1.5 ml microfuge tubes that were precoated with the oxidizing agent lodo-Gen (Pierce) under nitrogen gas, according to the manufacturer's instructions. The ratio of 1251 to monomeric scFv was 500 ,Ci: 100 ,tg in the presence of 100 ,tg of lodoGen. The iodination reaction was allowed to proceed for 10 min on ice in a total volume of not more than 500,l of borate buffer pH 8.6 [one part 0.1 M borate to one part 0.9% (v/v) sodium chloride]. lodinated scFv was separated from '251+ by gel filtration on a Sephadex G25 column (PD10, Pharmacia). The column was pre-blocked with 5% BSA in PBS followed by six void-volume washes in PBS prior to loading of the iodination reaction mixture. lodinated scFv were eluted in PBS and stored at 4°C for not more than 5 days prior to administration to mice. Samples of radiolabelled scFv were checked prior to in vivo administration to ensure against dimerized or degraded material.
Specific activity of 1251-labelled scFv
The specific activity of the protein was estimated by counting serially diluted aliquots of the peak fraction (in PBS/1% BSA) in a gamma-counter (Cobra II, Canberra Packard). The calculated specific activity of the labelled scFv was between 0.5-2 pCi ,tg-'. Stability of the labelled conjugate was measured by thin layer chromatography on silica gel using 10% trichloracetic acid (TCA) as the mobile phase: this confirmed that for all ['251 ]scFv, 95-97% of the counts were TCA precipitable. CEA reactivity of the labelled scFv was confirmed by measuring binding to a 0.5-ml CEA-Sepharose column, provided by the Department of Clinical Oncology, Royal Free Hospital. A 50 pi aliquot of ['251 ]scFv, diluted to give approximately 50 000 c.p.m. was loaded onto the column and three voidvolume washes with PBS removed CEA non-reactive material, which was retained for gamma counting. The percentage of bound (CEA reactive) ['251 ]scFv was measured from material eluted with 3 M ammonium thiocyanate and gamma counting as above. The percentage CEA binding of labelled CEA-specific human scFv was compared with that of a human scFv specific for fluorescein (FITC-E2): this scFv exhibited no cross-reactivity to CEA by ELISA.
LS1 74T xenografts
LS174T is a human colon adenocarcinoma cell line maintained by serial passage in outbred MF1 athymic nude (niulnu) mice. In nude mice it produces moderately differentiated CEA-producing adenocarcinomas that secrete no measurable CEA into the circulation (Pedley et al, 1993) . Tumour localization of both murine and chimaeric CEAspecific antibodies, antibody fragments and scFv has been demonstrated using this tumour xenograft model (Harwood et al, 1985; King et al, 1994; Verhaar et al, 1995; Hu et al, 1996) . The biodistribution and tumour localization of ['251 ]scFv were examined in female MFI nulnu mice (weighing 20-25 g) bearing heterotransplanted LS 174T tumours (at a mean size of 650 mg; range 500-800 mg).
Biodistribution studies All [1251] scFv (0.1 mg ml-') were diluted in PBS and/or unlabelled scFv to achieve a radioactive concentration of between 50-100 pCi ml-' for injection. Groups of mice each received a single 0.1 ml (10 ,ug; 5-10 tCi) bolus dose of one of the eight antibodies, in the lateral tail vein. A 10 ,l aliquot was retained and the c.p.m. measured to confirm the mean injected dose. Groups of four mice were necropsied at various times from 3 h to 48 h following injection. Samples of blood, liver, kidney, lung, spleen, colon, skeletal muscle, femur and tumour were removed, weighed and suspended through an equivalent volume of 7 M potassium hydroxide prior to gamma counting. Incorporated radioactive counts were expressed per g of tissue as a percentage of the measured injected dose.
RESULTS

Purification of monomeric scFv for in vitro and in vivo experiments
In order to maximize the consistency of the experimental results, all scFv listed in Table 1 were purified by IMAC and FPLC then quantitated spectrophotometrically and analysed by non-reducing SDS-PAGE. Gel analysis was carried out because all scFv had been cloned into a pUC-based vector (for soluble expression in the absence of gene III) with a free cysteine residue at the carboxy terminus. This allowed site-specific modification of the scFv for studies reported elsewhere; however, it also had the effect of leading to dimer formation during scFv extraction. As this study aimed to correlate the biological properties of scFv with the off-rate component of affinity, all clones were purified as monomers to eliminate effects of bivalency.
Immunocytochemistry on fixed tissue sections Clones CEA6, HBB 1, T06D10, T06D4, T06D12 and TO6D1, as well as MFE23 and a negative control scFv Hb-1 (Parsons et al, 1996) , were examined for staining of ten samples each of normal human colon, colonic polyps/adenomas and colonic adenocarcinomas. No scFv showed completely uniform staining of every sample in a panel of ten, although a clear consensus could be reached: all CEA-specific clones stained moderately differentiated to well-differentiated colonic adenocarcinomas the most intensely, with less intense staining of colonic polyps and adenomas and weak to moderate staining of normal colon tissues. Staining of moderately differentiated tumours was localized to the basal surfaces of glands and within the lumen. Staining of well-differentiated tumours was confined to the mucin-producing goblet cells. Where staining of normal colon was seen, it was mainly located on normal surface epithelium, goblet cells and crypt epithelium. Figure I shows the staining of normal vs malignant colon tissue for CEA6, TO6D I I (the clone with the greatest difference in Kd from CEA6) and the negative control Hb-1. Neither TO6D 11 nor any of the other affinity-matured clones (not shown) showed any broad shift in specificity relative to CEA6 when analysed on these tissues. (Vaughan et al, 1996) , as did all of the affinity-matured clones (Figure 2A ). The extent of fluorescent staining seen was less than that routinely observed with CEA-specific bivalent mAbs (data not shown), but in all cases the cell population stained specifically with scFv was homogeneous.
In these experiments, we used the immortalized Chang human liver cell line as a negative control for CEA expression. We observed that CEA6 consistently showed crossreactivity to a subpopulation of Chang cells, as did HBB 11 and TO6D 12 to a lesser extent, while the remainder of the affinity matured clones showed no crossreactivity ( Figure 2B ). However, the crossreactive component in CEA6 was not observed on immunocytochemical staining of sections of normal human liver (data not shown).
CEA-reactivity of 1251-labelled scFv
The estimated efficiency of the lodoGen method for '251-labelling of scFv ranged from 10-40% and yielded products with specific activities in the range 0.5-2 pCi jg-'. This assumed that <95% of ["i51]scFv bound to pre-blocked Sephadex G25 following separation of labelled scFv from free iodine in the iodination reaction. This assumption is supported by the fact that 93-97% of incorporated counts in the first column-eluted radioactive peak was TCA precipitable (and remained Figure 3A and B). The percentage of injected dose (%ID) associated with tumour at 24 h was in the range typically seen with scFv (Huston et al, 1993 Figure 5B) ; the kidney was the route of excretion for all (1998) 78(2), 181-188 ratios in mice, of particular significance as MFE23 has been shown to have clinical utility; (2) in a single study (the second described above), T06D12 had exhibited similar properties to CEA6 and (3) in the same experiment, TO6D4 had generated the highest %ID g-' in tumour ( Figure 5A ). For the purpose of this study, a greater range of time points (3 h, 6 h, 18 h and 24 h) was examined. The data are summarized in Table 2 .
['251]CEA6 achieved T/B ratios of 14:1 at 18 h which had persisted at 24 h (0.5%ID g-' tumour), data consistent with the previous two studies. The biodistribution data generated for ['21 ]TO6D4 also appeared to support the findings of the previous study, with a higher %ID in tumour (1.5%) at 24 h p.i. and lower T/B ratio (4.5: 1). Again, the lower kidney:blood ratio for ['251 (Table 2 ) but, in this study, the T/B ratio appeared to be lower than that measured previously (6.6:1 as compared with 11:1).
DISCUSSION
We have previously described the isolation by phage display of a CEA specific scFv, CEA6, from a large unimmunized human library (Vaughan et al, 1996) . The dissociation constant of CEA6 for CEA is in the nanomolar range (7.7 x 10-9 M), which is typical of antibodies isolated from very large repertoires (Perelson and Oster, 1979; Griffiths et al, 1994; Vaughan et al, 1996) . Our early work showed that the antibody binds CEA-expressing cells by flow cytometry and immunocytochemistry, and localizes to CEA-expressing human tumour xenografts in nude mice. Because CEA6 had fulfilled the specificity requirements as a potential human tumour targeting agent, it was subjected to affinity maturation using a combination of low redundancy mutagenesis in CDR3 of heavy and light chains and light chain shuffling . Selection for clones with longer off-rates (KO,,) than CEA6 was achieved by solution selection in the presence of excess free antigen (Hawkins et al, 1992) .
Our previous work reported the antigenic specificity and binding kinetics of the CEA6-derived mutants (Osboum et al, 1996) . Our longer term objective was to determine whether the off-rate component of affinity would influence the amount of antibody associated with tumour at different times after intravenous administration. We carried out the in vivo experiments with CEA6 and all five mutant scFv (HBB 11, TO6D 10, T06D4, TO6D 12 and TO6D 11), spanning a range of Ko09 values from 6.2 x 10-3 s-to 9.0 x 104 s-'. To eliminate the role of avidity effects in the biodistribution profiles, purified monomeric fractions of scFv were used for the experiments, because we and others have observed a tendency of scFv to form dimers (Griffiths et al, 1992) .
One of the advantages of using 1211 as the labelling radioisotope is that the lodoGen method allows more than one atom of iodine to be introduced per scFv, thereby increasing the sensitivity of detection. Labelling of scFv with Technetium-99m at single specific sites remote from the binding domains has been successful for imaging applications (Liberatore et al, 1995; Verhaar et al, 1996) but is less sensitive than iodine. However, one disadvantage of iodination is that it modifies tyrosine residues including those in the antigen binding site. CEA6 and the mutants derived from it have at least 14 tyrosine residues available for attachment of iodine, some of which are in complementarity-determining regions, yet in the affinity chromatography experiments described here, none of the clones showed reduced CEA binding specificity following radioiodination. This was subsequently confirmed in their tumour localization profiles. Rapid fractional clearance of murine scFv from the blood after intravenous administration has often been reported to be the determining factor in the concentration of scFv taken up into tumour (Colcher et al, 1990; Milenic et al, 1991; Savage et al, 1993) . For all 1'21-labelled scFv examined in this study, clearance of the bulk of the injected dose was primarily via the kidney at early time points. There was no significant uptake of radioactivity into any of the normal tissues at the time points tested, although the degree of kidney retention over time varied from clone to clone. The lower tumour-kidney ratio at 24 h, measured for scFv T06D4, suggested a rate of clearance more typical of Fab' or F(ab')2 fragments (Colcher et al, 1990;  (1993) concluded that a high-affinity mAb would achieve improved tumour uptake and longer residence time at the tumour. However, they also conceded that the bulk of an injected high affinity antibody would be absorbed by CEA shed in the serum and by cells at the tumour periphery, whereas a lower affinity mAb would have the chance to penetrate to CEA positive cells deeper in the tumour and thereby result in a better therapeutic agent. As well as the different patterns of in vivo behaviour of the panel of scFv, flow cytometry has revealed differences in extent of binding to a human liver cell line: CEA6, HBB 11 and, to a very small extent, T06D 12 were partially cross-reactive with Chang cells, while the remaining affinity-matured clones were not. Although structurally related markers of the CEA superfamily are known to be expressed on liver (Hinoda et al, 1988) , the binding of CEA6, HBB 11 and T06D 12 cannot be explained as cross-reactivity to such molecules, as normal human liver stained negative by immunocytochemistry for all of the scFv in the study. It is not possible to explain the cross-reactive component in these antibodies on the basis of sequence, as there is no light chain sequence consensus between CEA6, HBB 11 and T06DI2 that distinguishes them from the other clones . Likewise, the extent of liver cell binding does not appear to increase with increasing affinity for CEA. However, because we had not observed increased liver retention of ['251 It has recently been shown that a radiolabelled scFv specific for human CEA is a potent tumour imaging agent, achieving exceptional T/B ratios in patients . The scFv in question, MFE23, was isolated from a phage display library constructed from a CEA-immunized mouse and has an affinity for CEA of 2.5 x 10-9 M (Chester et al, 1994) . Our work demonstrates that CEA6 compares very favourably with MFE23 in a mouse tumour xenograft model and has an affinity for CEA in the same range. However, one clear distinction between the two antibodies is that while MFE23 was derived from antigenic selection in a mouse, CEA6 has been selected directly from a non-immunized human library and functions in tumour targeting without additional affinity maturation. This study has shown that CEA6 has all of the essential properties for reformatting as a higher molecular weight molecule to prolong its in vivo half-life and thereby improve its performance as a fully human therapeutic agent. These studies are currently in progress.
